| Muscle Spasm – Pipeline Review, H1 2012 |
| Publication Date |
Jun 2012 |
| Publisher |
Global Markets Direct |
| Product Type |
Report |
| Pages |
29 |
| Single User License |
$ 500.00 |
| Site User License |
$ 1000.00 |
| Corporate User License |
$ 1500.00 |
|
|
Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.
|
Muscle Spasm – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Muscle Spasm - Pipeline Review, H1 2012', provides an overview of the Muscle Spasm therapeutic pipeline. This report provides information on the therapeutic development for Muscle Spasm, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscle Spasm. 'Muscle Spasm - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Muscle Spasm.
- A review of the Muscle Spasm products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Muscle Spasm pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Muscle Spasm.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Muscle Spasm pipeline depth and focus of Muscle Spasm therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Muscle Spasm Therapeutic Products under Development, Key Players in Muscle Spasm Therapeutics, Muscle Spasm Pipeline Overview, Muscle Spasm Pipeline, Muscle Spasm Pipeline Assessment
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Muscle Spasm Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Muscle Spasm 6
Muscle Spasm Therapeutics under Development by Companies 8
Late Stage Products 9
Comparative Analysis 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Muscle Spasm Therapeutics – Products under Development by Companies 11
Companies Involved in Muscle Spasm Therapeutics Development 12
Eisai Co., Ltd. 12
Sanochemia Pharmazeutika AG 13
Muscle Spasm – Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Combination Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Drug Profiles 20
Tolperisone - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Tolperisone - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
E2000 + Diclofenac Sodium - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Muscle Spasm Therapeutics – Discontinued Products 25
Muscle Spasm Therapeutics - Dormant Products 26
Muscle Spasm – Product Development Milestones 27
Featured News & Press Releases 27
May 16, 2011: Watson Launches Generic AMRIX 27
Dec 01, 1994: Royce laboratories, inc. receives FDA approval for Cyclobenzaprine hydrochloride 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29
List of Tables
List of Tables
Number of Products Under Development for Muscle Spasm, H1 2012 6
Products under Development for Muscle Spasm – Comparative Analysis, H1 2012 7
Number of Products under Development by Companies, H1 2012 8
Comparative Analysis by Late Stage Development, H1 2012 9
Comparative Analysis by Mid Clinical Stage Development, H1 2012 10
Products under Development by Companies, H1 2012 11
Eisai Co., Ltd., H1 2012 12
Sanochemia Pharmazeutika AG, H1 2012 13
Assessment by Monotherapy Products, H1 2012 14
Assessment by Combination Products, H1 2012 15
Assessment by Stage and Route of Administration, H1 2012 17
Assessment by Stage and Molecule Type, H1 2012 19
Muscle Spasm Therapeutics – Discontinued Products 25
Muscle Spasm Therapeutics – Dormant Products 26
List of Figures
List of Figures
Number of Products under Development for Muscle Spasm, H1 2012 6
Products under Development for Muscle Spasm – Comparative Analysis, H1 2012 7
Products under Development by Companies, H1 2012 8
Late Stage Products, H1 2012 9
Mid Clinical Stage Products, H1 2012 10
Assessment by Monotherapy Products, H1 2012 14
Assessment by Combination Products, H1 2012 15
Assessment by Route of Administration, H1 2012 16
Assessment by Stage and Route of Administration, H1 2012 17
Assessment by Molecule Type, H1 2012 18
Assessment by Stage and Molecule Type, H1 2012 19
| Title |
Date |
Price |
|
| By Netscribes (India) Pvt. Ltd. |
|
|
May 2012 |
$0.00 |
| Medical Devices Market in Russia 2009-2013 |
| By Infiniti Research Ltd |
| Medical devices comprise surgical equipment & appliances, diagnostic devices, X-ray, ophthalmic equipment, laboratory devices & diagnostics, dental equipment, medical disposables and others.The Russia ...Read More |
|
Mar 2010 |
$1500.00 |
|
|
Jan 2012 |
$250.00 |
|
|
Jan 2010 |
$149.00 |
|
|
Jan 2010 |
$149.00 |
| 2010 U.S. HMO Medical Centers Industry Report |
| By Barnes Reports |
| The U.S HMO Medical Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 20 ...Read More |
|
Jan 2010 |
$149.00 |
|
|
Oct 2009 |
$149.00 |
|
|
Jan 2010 |
$149.00 |
|
|
Oct 2009 |
$149.00 |
| 2010 U.S. Medical Laboratories Industry Report |
| By Barnes Reports |
| The Medical Laboratories Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 2011 ...Read More |
|
Oct 2009 |
$149.00 |
|
| |
|
|
|
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161 |
|
|
| |
  
|
| |
|
|
|
